Sign in or create an account to add this stock to your watchlist.
About Flex Pharma (NASDAQ:FLKS)
Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis; and two Phase 2 clinical trials in the United States for the treatment of patients with motor neuron disease in amyotrophic lateral sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT product online through its e-commerce Website, as well as through specialty retailers. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLKS
CUSIPN/A
Phone617-874-1821
Debt
Debt-to-Equity RatioN/A
Current Ratio6.22
Quick Ratio6.12
Price-To-Earnings
Trailing P/E Ratio-1.96
Forward P/E Ratio-2.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.27 million
Price / Sales55.31
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book2.41
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-34,430,000.00
Net Margins-2,842.07%
Return on Equity-104.48%
Return on Assets-90.59%
Miscellaneous
Employees22
Outstanding Shares18,010,000
Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
How were Flex Pharma's earnings last quarter?
Flex Pharma (NASDAQ:FLKS) announced its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.04. The biotechnology company earned $0.18 million during the quarter, compared to analyst estimates of $0.30 million. Flex Pharma had a negative net margin of 2,842.07% and a negative return on equity of 104.48%. View Flex Pharma's Earnings History.
What price target have analysts set for FLKS?
4 equities research analysts have issued 12-month price objectives for Flex Pharma's stock. Their predictions range from $6.00 to $40.00. On average, they anticipate Flex Pharma's share price to reach $17.50 in the next twelve months. View Analyst Ratings for Flex Pharma.
What are Wall Street analysts saying about Flex Pharma stock?
Here are some recent quotes from research analysts about Flex Pharma stock:
- 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (5/7/2018)
- 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in MS showed statistically significant reduction of 27.3% (p=0.001) in frequency of cramps and a 1.4-day increase in the number of cramp-free days (p=0.0457)." (3/27/2018)
Who are some of Flex Pharma's key competitors?
Some companies that are related to Flex Pharma include Ardelyx (ARDX), Selecta Biosciences (SELB), Vital Therapies (VTL), Kindred Biosciences (KIN), Celyad (CYAD), Viking Therapeutics (VKTX), resTORbio (TORC), Ocular Therapeutix (OCUL), AVEO Pharmaceuticals (AVEO), Avadel Pharmaceuticals (AVDL), Aratana Therapeutics (PETX), Scpharmaceuticals (SCPH), Recro Pharma (REPH), Melinta Therapeutics (MLNT) and Aeglea Bio Therapeutics (AGLE).
Who are Flex Pharma's key executives?
Flex Pharma's management team includes the folowing people:
- Dr. Christoph H. Westphal, Co-Founder & Chairman (Age 51)
- Dr. Roderick MacKinnon Ph.D., M.D., Co-Founder, Co-Chair of Scientific Advisory Board and Director (Age 62)
- Dr. Thomas C. Wessel M.D., Ph.D., Chief Medical Officer (Age 62)
- Dr. William K. McVicar, Pres & CEO (Age 60)
- Mr. Robert Hadfield, Advisor (Age 40)
When did Flex Pharma IPO?
(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.
Has Flex Pharma been receiving favorable news coverage?
Press coverage about FLKS stock has trended somewhat positive recently, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a news sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.69 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Flex Pharma's major shareholders?
Flex Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include C WorldWide Group Holding A S (1.19%), Millennium Management LLC (0.33%) and JPMorgan Chase & Co. (0.21%). Company insiders that own Flex Pharma stock include Christoph H Westphal and John P Mccabe. View Institutional Ownership Trends for Flex Pharma.
Which major investors are selling Flex Pharma stock?
Which major investors are buying Flex Pharma stock?
FLKS stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and Millennium Management LLC. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal and John P Mccabe. View Insider Buying and Selling for Flex Pharma.
How do I buy shares of Flex Pharma?
Shares of FLKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flex Pharma's stock price today?
One share of FLKS stock can currently be purchased for approximately $3.90.
How big of a company is Flex Pharma?
Flex Pharma has a market capitalization of $69.17 million and generates $1.27 million in revenue each year. The biotechnology company earns $-34,430,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Flex Pharma employs 22 workers across the globe.
How can I contact Flex Pharma?
Flex Pharma's mailing address is 800 Boylston Street 24thFloor, Boston MA, 02199. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]
MarketBeat Community Rating for Flex Pharma (FLKS)
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe FLKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Flex Pharma (NASDAQ:FLKS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Flex Pharma in the last 12 months. Their average twelve-month price target is $17.50, suggesting that the stock has a possible upside of 348.72%. The high price target for FLKS is $40.00 and the low price target for FLKS is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.80 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.50 | $9.50 | $10.80 | $11.00 |
| Price Target Upside: | 348.72% upside | 34.75% upside | 168.66% upside | 214.29% upside |
Flex Pharma (NASDAQ:FLKS) Consensus Price Target History
Flex Pharma (NASDAQ:FLKS) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Flex Pharma (NASDAQ:FLKS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Flex Pharma (NASDAQ FLKS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.62%
Institutional Ownership Percentage: 27.80%
Flex Pharma (NASDAQ FLKS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/8/2016 | Christoph H Westphal | Insider | Buy | 7,000 | $7.31 | $51,170.00 | 3,941,118 |  |
| 11/7/2016 | Christoph H Westphal | Insider | Buy | 8,870 | $5.70 | $50,559.00 | 3,934,118 | |
| 11/7/2016 | John P Mccabe | VP | Buy | 1,650 | $6.01 | $9,916.50 | 1,650 | |
| 6/23/2016 | Christoph H Westphal | CEO | Buy | 2,700 | $11.28 | $30,456.00 | 3,925,248 | |
| 6/22/2016 | Christoph H Westphal | CEO | Buy | 5,700 | $11.05 | $62,985.00 | 3,925,248 | |
| 6/21/2016 | Christoph H Westphal | CEO | Buy | 2,800 | $11.07 | $30,996.00 | 3,925,248 | |
| 6/20/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.18 | $67,080.00 | 3,925,248 | |
| 6/16/2016 | Christoph H Westphal | CEO | Buy | 5,800 | $11.17 | $64,786.00 | 3,925,248 | |
| 6/14/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $11.54 | $68,086.00 | 3,925,248 | |
| 6/10/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.94 | $71,640.00 | 3,925,248 | |
| 6/8/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $12.25 | $72,275.00 | 3,925,248 | |
| 6/6/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $12.56 | $75,360.00 | 3,925,248 | |
| 6/2/2016 | Christoph H Westphal | CEO | Buy | 10,000 | $12.99 | $129,900.00 | 3,925,248 | |
| 5/31/2016 | Christoph H Westphal | CEO | Buy | 22,300 | $12.68 | $282,764.00 | 3,925,248 | |
| 5/26/2016 | Christoph H Westphal | CEO | Buy | 28,600 | $12.84 | $367,224.00 | 3,925,248 | |
| 5/24/2016 | Christoph H Westphal | CEO | Buy | 30,334 | $12.42 | $376,748.28 | 3,925,248 | |
| 5/20/2016 | Christoph H Westphal | CEO | Buy | 7,914 | $11.06 | $87,528.84 | 3,925,248 | |
| 5/18/2016 | Christoph H Westphal | CEO | Buy | 33,400 | $11.10 | $370,740.00 | 3,925,248 | |
| 5/16/2016 | Christoph H Westphal | CEO | Buy | 15,469 | $10.25 | $158,557.25 | 3,925,248 | |
| 5/12/2016 | Christoph H Westphal | CEO | Buy | 30,217 | $10.12 | $305,796.04 | 3,925,248 | |
| 5/10/2016 | Christoph H Westphal | CEO | Buy | 30,109 | $9.94 | $299,283.46 | 3,925,248 | |
| 3/24/2016 | Christoph H Westphal | CEO | Buy | 49,563 | $11.06 | $548,166.78 | 3,925,248 | |
| 3/22/2016 | Christoph H Westphal | CEO | Buy | 23,951 | $11.78 | $282,142.78 | | |
| 3/21/2016 | Christoph H Westphal | CEO | Buy | 48,058 | $11.74 | $564,200.92 | 3,925,248 | |
| 3/18/2016 | Christoph H Westphal | CEO | Buy | 37,574 | $11.00 | $413,314.00 | 3,925,248 | |
| 3/16/2016 | Christoph H Westphal | CEO | Buy | 38,379 | $10.23 | $392,617.17 | 3,925,248 | |
| 3/15/2016 | Michelle Stacy | Director | Buy | 2,585 | $9.63 | $24,893.55 | 2,585 | |
| 3/14/2016 | Thomas Wessel | Insider | Buy | 20,000 | $7.94 | $158,800.00 | 49,064 | |
| 3/11/2016 | Christoph H Westphal | CEO | Buy | 89,680 | $7.00 | $627,760.00 | 3,925,248 | |
| 3/11/2016 | Roderick Mackinnon | Director | Buy | 10,000 | $7.03 | $70,300.00 | 431,277 | |
| 12/14/2015 | Christoph H Westphal | CEO | Buy | 927 | $12.01 | $11,133.27 | 3,925,248 | |
| 12/7/2015 | Christoph H Westphal | CEO | Buy | 907 | $12.02 | $10,902.14 | 3,924,321 | |
| 11/19/2015 | Marc D Kozin | Director | Buy | 4,500 | $11.38 | $51,210.00 | 4,500 | |
| 11/16/2015 | Christoph H Westphal | CEO | Buy | 1,001 | $10.78 | $10,790.78 | 3,921,556 | |
| 11/9/2015 | Christoph H Westphal | CEO | Buy | 1,000 | $11.03 | $11,030.00 | 3,920,555 | |
| 10/26/2015 | Christoph H Westphal | CEO | Buy | 1,043 | $10.55 | $11,003.65 | 3,918,588 | |
| 10/19/2015 | Christoph H Westphal | CEO | Buy | 1,018 | $10.61 | $10,800.98 | 3,917,545 | |
| 9/28/2015 | Christoph H Westphal | CEO | Buy | 924 | $11.18 | $10,330.32 | 3,914,735 | |
| 3/30/2015 | Christoph H Westphal | CEO | Buy | 272 | $20.52 | $5,581.44 | | |
(Data available from 1/1/2013 forward)
Flex Pharma (NASDAQ FLKS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | MEI Pharma (MEIP) and Flex Pharma (FLKS) Head to Head Review
www.americanbankingnews.com - May 21 at 9:22 PM |
| Flex Pharma (FLKS) Expected to Announce Quarterly Sales of $290,000.00
www.americanbankingnews.com - May 20 at 4:21 AM |
| Zacks: Brokerages Anticipate Flex Pharma (FLKS) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - May 18 at 12:44 PM |
| Flex Pharma (FLKS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 8 at 12:16 AM |
| Flex Pharma to Post Q2 2018 Earnings of ($0.39) Per Share, Jefferies Group Forecasts (FLKS)
www.americanbankingnews.com - May 7 at 2:13 AM |
| Flex Pharma (FLKS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 5 at 1:33 AM |
| ValuEngine Upgrades Flex Pharma (FLKS) to "Sell"
www.americanbankingnews.com - May 4 at 12:13 AM |
| Flex Pharma (FLKS) Issues Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 7:29 PM |
| Flex Pharma (FLKS) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - May 3 at 4:31 PM |
 | Edited Transcript of FLKS earnings conference call or presentation 2-May-18 1:00pm GMT
finance.yahoo.com - May 3 at 8:41 AM |
 | Flex Pharma's (FLKS) CEO Bill McVicar on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 5:11 PM |
| Flex Pharma beats by $0.03, misses on revenue
seekingalpha.com - May 2 at 8:47 AM |
| Flex Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 8:47 AM |
| Zacks: Brokerages Anticipate Flex Pharma (FLKS) Will Post Quarterly Sales of $300,000.00
www.americanbankingnews.com - May 2 at 2:02 AM |
| Does Flex Pharma Inc’s (NASDAQ:FLKS) Latest Financial Perfomance Look Strong?
finance.yahoo.com - May 1 at 8:51 AM |
| Zacks: Analysts Anticipate Flex Pharma (FLKS) to Post -$0.50 EPS
www.americanbankingnews.com - April 30 at 7:12 PM |
| Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018
finance.yahoo.com - April 25 at 5:10 PM |
| Flex Pharma (FLKS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM |
| Flex Pharma (FLKS) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 11:10 AM |
| $300,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - April 15 at 2:14 AM |
| Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Earnings of -$0.50 Per Share
www.americanbankingnews.com - April 13 at 9:16 PM |
| Flex Pharma Inc (FLKS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 10 at 1:41 AM |
| Flex Pharma (FLKS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 8 at 12:40 AM |
| Flex Pharma (FLKS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:53 PM |
| Flex Pharma (FLKS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM |
| Flex Pharma (FLKS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:10 PM |
| Brokerages Expect Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $300,000.00
www.americanbankingnews.com - March 29 at 2:28 AM |
| Flex Pharma (FLKS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 28 at 10:22 PM |
 | Flex Pharma (FLKS) Announces Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis
www.streetinsider.com - March 28 at 8:59 AM |
| Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.50 Earnings Per Share
www.americanbankingnews.com - March 27 at 11:14 PM |
| Flex Pharma (FLKS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 27 at 9:53 AM |
| Flex Pharma's FLX-787 shows treatment effect in MS patients with cramps/spasms in exploratory study; shares up 6%
seekingalpha.com - March 26 at 4:53 PM |
| Today’s Research Reports on Stocks to Watch: Flex Pharma, Inc. and Alexion Pharmaceuticals
finance.yahoo.com - March 16 at 8:53 AM |
| Flex Pharma Inc (FLKS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 16 at 1:36 AM |
| Flex Pharma (FLKS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM |
| Research Analysts Offer Predictions for Flex Pharma Inc's Q1 2018 Earnings (FLKS)
www.americanbankingnews.com - March 12 at 2:30 AM |
| Flex Pharma (FLKS) Posts Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - March 8 at 10:29 AM |
| Cantor Fitzgerald Analysts Give Flex Pharma (FLKS) a $6.00 Price Target
www.americanbankingnews.com - March 7 at 4:15 PM |
 | Flex Pharma Reports Year End 2017 Financial Results
www.bizjournals.com - March 7 at 8:51 AM |
| Should You Buy Flex Pharma Inc (NASDAQ:FLKS) Now?
finance.yahoo.com - March 7 at 8:51 AM |
| Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018
finance.yahoo.com - February 28 at 5:38 PM |
| $360,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - February 23 at 2:02 AM |
| Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.85 EPS
www.americanbankingnews.com - February 21 at 11:14 PM |
| Flex Pharma Inc (FLKS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 19 at 1:32 AM |
| Zacks Investment Research Upgrades Flex Pharma (FLKS) to Hold
www.americanbankingnews.com - February 15 at 11:22 PM |
| Flex Pharma Inc to Post FY2018 Earnings of ($1.68) Per Share, Jefferies Group Forecasts (FLKS)
www.americanbankingnews.com - February 15 at 11:40 AM |
| Jefferies Group Comments on Flex Pharma Inc's FY2022 Earnings (FLKS)
www.americanbankingnews.com - February 14 at 4:12 PM |
| New Study Shows HOTSHOT™ Provides Relief From Muscle Soreness For Athletes Of All Types
finance.yahoo.com - February 8 at 8:29 AM |
| Flex Pharma Presenting at BIO CEO on February 13, 2018
finance.yahoo.com - February 6 at 4:00 PM |
| Summit Therapeutics (SMMT) vs. Flex Pharma (FLKS) Head-To-Head Contrast
www.americanbankingnews.com - February 6 at 1:19 PM |
Flex Pharma (NASDAQ:FLKS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Flex Pharma (NASDAQ:FLKS) Income Statement, Balance Sheet and Cash Flow Statement
Flex Pharma (NASDAQ FLKS) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
